New and Future Parenteral Therapies for the Management of Lipid Disorders

被引：11
作者：
Garcia, Roberto [1 ]
Burkle, Jaime [2 ]
机构：
[1] Inst Mexicano Seguro Social, Hosp Cardiol 34, Unidad Med Alta Especialidad, Monterrey, NL, Mexico
[2] Piedmont Heart Inst, Atlanta, GA USA
来源：
ARCHIVES OF MEDICAL RESEARCH | 2018年 / 49卷 / 08期
关键词：
Cardiovascular disease; LDL; PCSK9; sIRNA; Antisense oligonucleotides; Inclinsiran; Alipogene; Dyslipidemia; Lipid disorders therapy; HIGH CARDIOVASCULAR RISK; STATIN THERAPY; LDL CHOLESTEROL; REDUCING LIPIDS; DOUBLE-BLIND; ADD-ON; ALIROCUMAB; EFFICACY; SAFETY; HYPERCHOLESTEROLEMIA;
D O I：
10.1016/j.arcmed.2019.01.001
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Cardiovascular disease (CVD) is the leading cause of death in the world. According to the World Health Organization, an estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 5% are due to myocardial infarction and stroke. Dyslipidemia is known as the major risk factor of atherosclerotic cardiovascular disease. With current therapies, about 60% of high-risk CVD patients do not achieve LDL-C goals, and in patients with familiar hypercholesterolemia (FH) at maximum intensity statin treatment, only 20% achieve LDL-C goals. We discuss new and future parenteral therapies for the management of lipid disorders. (C) 2019 IMSS. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：538 / 547
页数：10
相关论文
共 48 条
[1]   Antisense oligonucleotide technologies in drug discovery [J].
Aboul-Fadl, Tarek .
EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (04) :285-288
[2]   New Drugs for Treating Dyslipidemia: Beyond Statins [J].
Ahn, Chang Ho ;
Choi, Sung Hee .
DIABETES & METABOLISM JOURNAL, 2015, 39 (02) :87-94
[3]  
[Anonymous], PANCREATOLOGY
[4]  
[Anonymous], 2013, Summary of Product Characteristics Bridion
[5]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[6]   Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial [J].
Bays, Harold ;
Gaudet, Daniel ;
Weiss, Robert ;
Ruiz, Juan Lima ;
Watts, Gerald F. ;
Gouni-Berthold, Ioanna ;
Robinson, Jennifer ;
Zhao, Jian ;
Hanotin, Corinne ;
Donahue, Stephen .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (08) :3140-3148
[7]   Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials [J].
Boekholdt, S. Matthijs ;
Hovingh, G. Kees ;
Mora, Samia ;
Arsenault, Benoit J. ;
Amarenco, Pierre ;
Pedersen, Terje R. ;
LaRosa, John C. ;
Waters, David D. ;
DeMicco, David A. ;
Simes, R. John ;
Keech, Antony C. ;
Colquhoun, David ;
Hitman, Graham A. ;
Betteridge, John ;
Clearfield, Michael B. ;
Downs, John R. ;
Colhoun, Helen M. ;
Gotto, Antonio M., Jr. ;
Ridker, Paul M. ;
Grundy, Scott M. ;
Kastelein, John J. P. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (05) :485-494
[8]  
Brugts JJ, 2009, BMJ-BRIT MED J, V339, P36
[9]   Optimizing Non-Pharmacologic Management of Hypertriglyceridemia [J].
Byrne, Alexandra ;
Makadia, Sunal ;
Sutherland, Aimee ;
Miller, Michael .
ARCHIVES OF MEDICAL RESEARCH, 2017, 48 (06) :483-487
[10]   Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].
Cannon, Christopher P. ;
Blazing, Michael A. ;
Giugliano, Robert P. ;
McCagg, Amy ;
White, Jennifer A. ;
Theroux, Pierre ;
Darius, Harald ;
Lewis, Basil S. ;
Ophuis, Ton Oude ;
Jukema, J. Wouter ;
De Ferrari, Gaetano M. ;
Ruzyllo, Witold ;
De Lucca, Paul ;
Im, KyungAh ;
Bohula, Erin A. ;
Reist, Craig ;
Wiviott, Stephen D. ;
Tershakovec, Andrew M. ;
Musliner, Thomas A. ;
Braunwald, Eugene ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397
12345